Advertisement
Canada markets close in 1 hour 6 minutes

  • S&P/TSX

    21,854.22
    -157.50 (-0.72%)
     

  • S&P 500

    5,062.58
    -7.97 (-0.16%)
     

  • DOW

    38,435.67
    -68.02 (-0.18%)
     

  • CAD/USD

    0.7297
    -0.0024 (-0.32%)
     

  • CRUDE OIL

    82.84
    -0.52 (-0.62%)
     

  • Bitcoin CAD

    88,009.66
    -3,427.09 (-3.75%)
     

  • CMC Crypto 200

    1,397.00
    -27.10 (-1.90%)
     

  • GOLD FUTURES

    2,333.20
    -8.90 (-0.38%)
     

  • RUSSELL 2000

    1,990.50
    -12.15 (-0.61%)
     

  • 10-Yr Bond

    4.6580
    +0.0600 (+1.30%)
     

  • NASDAQ

    15,673.84
    -22.80 (-0.15%)
     

  • VOLATILITY

    16.02
    +0.33 (+2.10%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6821
    -0.0015 (-0.22%)
     
MARKETS LIVE BLOG:

STOCKS SHED GAINS, TESLA SURGES DAY AFTER EARNINGS

Tesla shares jump after EV maker vows to speed up launch of more affordable models

Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference

Entasis Therapeutics Holdings Inc.
·1 min read

WALTHAM, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming Cantor Fitzgerald Virtual Global Healthcare Conference to be held September 27-30, 2021.

Details of the Company’s participation can be found below:

Cantor Fitzgerald Virtual Global Healthcare Conference

Format: Company presentation and one-on-one investor meetings

Date: Thursday September 30, 2021

Time: 1:20 p.m. EDT

Webcast: https://wsw.com/webcast/cantor12/ettx/2120370

The webcast of the Company’s presentation will be accessible in the News & Events section of the Entasis website at https://www.entasistx.com/.

ADVERTISEMENT

About Entasis
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0462 (targeting multiple Gram-negative pathogens including Pseudomonas aeruginosa) and ETX0282CPDP (targeting Enterobacteriaceae infections). For more information, visit www.entasistx.com.

Entasis Contacts
Company:
Kyle Dow
Entasis Therapeutics
(781) 810-0114
kyle.dow@entasistx.com

Investor Relations:
Bruce Mackle
LifeSci Advisors
(929) 469-3859
bmackle@lifesciadvisors.com